A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures

被引:1
|
作者
Das, Agneesh Pratim [1 ,2 ]
Nandekar, Prajwal [3 ]
Mathur, Puniti [2 ]
Agarwal, Subhash M. [1 ,4 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, Noida, Uttar Pradesh, India
[2] Amity Univ Uttar Pradesh, Amity Inst Biotechnol, Noida, Uttar Pradesh, India
[3] Schrodinger India Pvt Ltd, Bengaluru, Karnataka, India
[4] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, I-7,Sect 39, Noida 201301, Uttar Pradesh, India
关键词
binding pose metadynamics; cross docking; drug discovery; EGFR; kinase; structure selection; virtual screening; NONCOVALENT INHIBITORS; RECEPTOR; DOCKING; RESISTANCE; BINDING;
D O I
10.1002/pro.4740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Virtual screening (VS) is a routine method to evaluate chemical libraries for lead identification. Therefore, the selection of appropriate protein structures for VS is an essential prerequisite to identify true actives during docking. But the presence of several crystal structures of the same protein makes it difficult to select one or few structures rationally for screening. Therefore, a computational prioritization protocol has been developed for shortlisting crystal structures that identify true active molecules with better efficiency. As identification of small-molecule inhibitors is an important clinical requirement for the T790M/L858R (TMLR) EGFR mutant, it has been selected as a case study. The approach involves cross-docking of 21 co-crystal ligands with all the structures of the same protein to select structures that dock non-native ligands with lower RMSD. The cross docking performance was then correlated with ligand similarity and binding-site conformational similarity. Eventually, structures were shortlisted by integrating cross-docking performance, and ligand and binding-site similarity. Thereafter, binding pose metadynamics was employed to identify structures having stable co-crystal ligands in their respective binding pockets. Finally, different enrichment metrics like BEDROC, RIE, AUAC, and EF1% were evaluated leading to the identification of five TMLR structures (5HCX, 5CAN, 5CAP, 5CAS, and 5CAO). These structures docked a number of non-native ligands with low RMSD, contain structurally dissimilar ligands, have conformationally dissimilar binding sites, harbor stable co-crystal ligands, and also identify true actives early. The present approach can be implemented for shortlisting protein targets of any other important therapeutic kinases.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors
    Zhang, Mingguang
    Yang, Yang
    Wang, Yunyun
    Wang, Jia
    Wu, Hongyan
    Zhu, Yongqiang
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2023, 71 (02) : 140 - 147
  • [32] Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
    Wang, Yue Feng
    Xiang, Xianhong
    Pei, Xiaojuan
    Li, Shuhua
    Tang, Cuilan
    Wang, Liantang
    Ke, Zun-Fu
    ONCOLOGY LETTERS, 2014, 8 (03) : 1039 - 1042
  • [33] Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study
    Fatima, Shehnaz
    Agarwal, Subhash Mohan
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2018, 38 (04) : 299 - 306
  • [34] Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
    Sun, Peiyuan
    Qu, Yana
    Wang, Yuna
    Wang, Jing
    Wang, Xuanjun
    Sheng, Jun
    JOURNAL OF CANCER, 2021, 12 (13): : 3900 - 3908
  • [35] A High-throughput Cell-based Screening for L858R/T790M Mutant Epidermal Growth Factor Receptor Inhibitors
    Lin, Wen-Hsing
    Song, Jen-Shin
    Lien, Tzu-Wen
    Chang, Chun-Yu
    Wu, Szu-Huei
    Huang, Yu-Wen
    Chang, Teng-Yuan
    Fang, Ming-Yu
    Yen, Kuei-Jung
    Chen, Chun-Hwa
    Chu, Chang-Ying
    Hsieh, Hsing-Pang
    Chen, Yi-Rong
    Chao, Yu-Sheng
    Hsu, John T-A
    ANTICANCER RESEARCH, 2012, 32 (01) : 147 - 151
  • [36] Isoliquiritigenin Induces Apoptosis and Inhibits Xenograft Tumor Growth of Human Lung Cancer Cells by Targeting Both Wild Type and L858R/T790M Mutant EGFR
    Jung, Sung Keun
    Lee, Mee-Hyun
    Lim, Do Young
    Kim, Jong Eun
    Singh, Puja
    Lee, Sung-Young
    Jeong, Chul-Ho
    Lim, Tae-Gyu
    Chen, Hanyong
    Chi, Young-In
    Kundu, Joydeb Kumar
    Lee, Nam Hyouck
    Lee, Charles C.
    Cho, Yong-Yeon
    Bode, Ann M.
    Lee, Ki Won
    Dong, Zigang
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (52) : 35839 - 35848
  • [37] Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer
    Wang, Xiaoxue
    Qin, Zhongxiang
    Qiu, Wenrui
    Xu, Kejia
    Bai, Yuting
    Zeng, Beilei
    Ma, Yakun
    Yang, Shuang
    Shi, Yi
    Fan, Yan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
  • [38] Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants
    Zhang, Haoyang
    Wu, Wenkui
    Feng, Chao
    Liu, Zhaogang
    Bai, Enhe
    Wang, Xueyuan
    Lei, Meng
    Cheng, Hao
    Feng, Huayun
    Shi, Jingmiao
    Wang, Jia
    Zhang, Zhao
    Jin, Tao
    Chen, Shanshan
    Hu, Shihe
    Zhu, Yongqiang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 135 : 12 - 23
  • [39] A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation
    Akher, Farideh Badichi
    Farrokhzadeh, Abdolkarim
    Ravenscroft, Neil
    Kuttel, Michelle M.
    BIOCHEMISTRY, 2019, 58 (41) : 4246 - 4259
  • [40] Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors
    Bhandari, Shashikant V.
    Kuthe, Pranali V.
    Patil, Shital M.
    Nagras, Om G.
    Sarkate, Aniket P.
    Chaudhari, Somdatta Y.
    Surve, Sandip V.
    CHEMISTRY & BIODIVERSITY, 2023, 20 (11)